이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Early Sepsis Detection Using NEWS2 and Circulating H3.1 Nucleosomes in Emergency Departments (DETECSEPS)

2026년 11월 11일 업데이트: Assistance Publique - Hôpitaux de Paris

Real-life Evaluation of the Impact of Early Detection of Sepsis With the NEWS2 Clinical Alert Score Combined to Circulating Concentrations of the H3.1 Nucleosome, on the Care Pathway of Adults Presenting to the Emergency Department With a Proven or Strongly Suspected Infection

DETECSEPS is a multicentre, randomized, open-label trial sponsored by Assistance Publique - Hôpitaux de Paris, under the scientific leadership of IHU SEPSIS - PROMETHEUS Comprehensive Sepsis Center, led by Professor Djillali Annane.

The study evaluates whether an early sepsis detection strategy combining the National Early Warning Score 2 (NEWS2) and circulating H3.1 nucleosome concentrations improves care pathways compared with usual care in adults presenting to emergency departments with suspected or confirmed infection and at least one risk factor for sepsis.

The strategy aims to support timely recognition and management of sepsis and to identify patients suitable for discharge with ambulatory follow-up when hospital admission is not otherwise indicated. The study will assess care pathway optimization at 24 hours, clinical outcomes, health-related quality of life, return to usual activities, and economic and environmental outcomes.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

상세 설명

DETECSEPS will enrol 1,000 adults across participating emergency departments. Participants will be randomized to either a diagnostic and management strategy guided by NEWS2 and circulating H3.1 nucleosome concentrations or usual care.

In the intervention group, the combined algorithm will guide clinical management and disposition according to the approved study protocol. The description of the algorithm will specify the actions associated with each combination of NEWS2 and H3.1 categories, including discharge with ambulatory follow-up, hospital admission, early sepsis management, and assessment for intensive care admission.

In the usual-care group, management will follow routine clinical practice. Research H3.1 results will not be disclosed to treating clinicians. The record will distinguish any NEWS2 score calculated specifically for research from physiological measurements and assessment tools available during routine care.

The primary outcome is the proportion of participants with an optimized care pathway at 24 hours. Participants will be followed for six months.

IHU SEPSIS - PROMETHEUS Comprehensive Sepsis Center is responsible for the scientific leadership of the study. Assistance Publique - Hôpitaux de Paris is the study sponsor.

연구 유형

중재적

등록 (추정된)

1000

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

      • Boulogne-Billancourt, 프랑스
        • Hôpital Ambroise Paré - AP-HP
        • 연락하다:
      • Lyon, 프랑스
        • Hôpital de la Croix Rousse - HCL
        • 연락하다:
      • Lyon, 프랑스
      • Lyon, 프랑스
        • Hôpital Édouard-Herriot - HCL
        • 연락하다:
      • Paris, 프랑스
        • Hôpital Bichat - AP-HP
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria

  1. All genders patients

  2. Aged of 18 years or older

  3. Proven or suspected infection

  4. At least one risk factor for sepsis (cf HAS recommendations) :

    • Age/frailty : >65 year; Clinical Frailty Scale ≥5; postpartum; Cognitive or motor disabilities; Implantable medical device; Recent surgery

    • Inborn immune deficit

    • Acquired immune deficit :

      • Diseases related : Cancer, Transplant patient, Chronic inflammatory or autoimmune disease, HIV, Asplenic anatomical or functional (Sickle cell disease)
      • Treatment related : Long-term corticotherapy, chemotherapy, Biotherapy, Cell therapy, radiotherapy, Immunosuppressive drugs,
    • Non immune disorders : Cirrhosis, chronic liver disease, chronic renal insufficiency, chronic cardiac failure, diabetes with complication or uncontrolled, malnutrition, previous episode of sepsis

  5. Informed consent

Exclusion Criteria:

  1. Refused to consent participating in the study,
  2. Any condition for which patient's primary physician will consider inappropriate enrolling patient in the study,
  3. Previous enrolment
  4. Pregnancy

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 특수 증상
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: NEWS2 and H3.1-guided diagnostic and management strategy

Clinical management and disposition will be guided by a prespecified algorithm combining NEWS2 and circulating H3.1 nucleosome concentrations. Decisions will follow the thresholds and management rules specified in the protocol.

Upon randomization, NEWS2 score and plasma level of H3.1 will be provided to the investigator and healthcare staff to guide management as per decision tree below :

  • If NEWS2 ≤2 AND H3.1 ≤50 ng/ml, the progression to sepsis is very unlikely or unlikely and the patient can be discharged home with ambulatory follow-up via teleconsultation.
  • If NEWS2 ≥5 and H3.1 ≥740 ng/ml, the progression to sepsis is likely or very likely and the 3-hour bundle of the Surviving Sepsis Campaign will be implemented and admission to the ICU within 6 hours of arrival at Emergency Department is required.
  • In any other case, patients will be monitored in the emergency department and NEWS 2 and plasma H3.1 level are recorded again at 3 hours.

This biomarker levels will be measured with Nu.Q® NETs/H3.1 automated system.

The result will not be disclosed to the investigators and healthcare staff in the control arm

The NEWS is based on a simple aggregate scoring system in which a score is allocated to physiological measurements, already recorded in routine practice, when patients present to, or are being monitored in hospital. Six simple physiological parameters form the basis of the scoring system:

  1. respiration rate
  2. oxygen saturation
  3. systolic blood pressure
  4. pulse rate
  5. level of consciousness or new confusion
  6. temperature

The result will not be disclosed to the investigators and healthcare staff in the control arm

다른: Usual care

Comparator arm description: Participants will receive usual diagnostic assessment and clinical management. H3.1 nucleosome concentrations will be measured for research purposes, but results will not be disclosed to treating clinicians.

This biomarker levels will be measured with Nu.Q® NETs/H3.1 automated system.

The result will not be disclosed to the investigators and healthcare staff in the control arm

The NEWS is based on a simple aggregate scoring system in which a score is allocated to physiological measurements, already recorded in routine practice, when patients present to, or are being monitored in hospital. Six simple physiological parameters form the basis of the scoring system:

  1. respiration rate
  2. oxygen saturation
  3. systolic blood pressure
  4. pulse rate
  5. level of consciousness or new confusion
  6. temperature

The result will not be disclosed to the investigators and healthcare staff in the control arm

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Proportion of patients with optimized care pathway
기간: 24 hours after inclusion

The best care pathway is defined by: discharge to home in the absence of confirmed sepsis, or hospitalization whenever any other reason than sepsis will mandate hospital admission

If sepsis is confirmed:

  • Implementation of good clinical practice recommendations within 3 hours of arrival at ED (3-hour bundle of the Surviving Sepsis Campaign & HAS recommendations)
  • ICU admission within 6 hours of arrival at ED
24 hours after inclusion

2차 결과 측정

결과 측정
측정값 설명
기간
Death rate
기간: At 6 months
At 6 months
Cumulative incidence of direct ICU admission
기간: Up to 6 months
Up to 6 months
Cumulative incidence of secondary ICU admission
기간: Up to 6 months

ie after admission to ward

Up to 6 months
Proportion of patients with cognitive, psychological, or physical sequelae
기간: Up to 6 months
Up to 6 months
Proportion of patients requiring renal, respiratory, or cardiovascular support
기간: Up to day 7

Organ support is defined as needing either respiratory, cardiovascular or renal support. Respiratory support is defined as high flow oxygen, non-invasive or invasive ventilation, extracorporeal membrane oxygenation or CO2 removal. Cardiovascular support is defined as ongoing infusion of any dose of any vasopressor or inotrope drug, or mechanical circulatory assistance. Renal support is defined by the requirement of renal replacement therapy regardless of treatment modalities. We will also compute the number of days free of organ support up to 7 and 28 days, with higher score indicating faster recovery

Up to day 7
Proportion of patients requiring renal, respiratory, or cardiovascular support
기간: Up to day 28

Organ support is defined as needing either respiratory, cardiovascular or renal support. Respiratory support is defined as high flow oxygen, non-invasive or invasive ventilation, extracorporeal membrane oxygenation or CO2 removal. Cardiovascular support is defined as ongoing infusion of any dose of any vasopressor or inotrope drug, or mechanical circulatory assistance. Renal support is defined by the requirement of renal replacement therapy regardless of treatment modalities. We will also compute the number of days free of organ support up to 7 and 28 days, with higher score indicating faster recovery

Up to day 28
Time to discharge to home
기간: Up to 6 months
Up to 6 months
Time to resume previous social and professional activities
기간: Up to 6 months
Up to 6 months
Quality of life - EQ-5D-5L
기간: At 6 months

The EQ-5D-5L is a patient-reported questionnaire assessing health-related quality of life across five dimensions, with higher index and EQ VAS scores indicating better health status

At 6 months
Quality of life - SF36
기간: At 6 months

The SF-36 is a 36-item patient-reported questionnaire assessing health-related quality of life across eight physical and mental health domains, with higher scores indicating better health status and functioning.

At 6 months
Cost of strategies and care pathways
기간: At 6 months

Costs of strategies and care pathways at 6 months with and without early H3.1 concentrations and the NEWS2 clinical score, incremental cost-effectiveness ratio calculated by the ratio of the difference in costs to the difference in survival without sequelae and without organ failure at 6 months.

At 6 months
Proportion of cases for which the combined diagnostic protocol is applied as intended
기간: Up to 6 months

e.g., correct use of NEWS2 and H3.1 nucleosome testing

Up to 6 months
Proportion of test results available below a meaningful clinical duration to allow for patient management.
기간: Up to 6 months
Up to 6 months
Proportion of appropriate integration of tests results within clinical workflow
기간: Up to 6 months
Up to 6 months
Proportion of avoided hospitalization among patients receiving the intervention
기간: Up to 6 months
Up to 6 months
Evolution of the proportion of eligible patients included over time
기간: Up to 6 months
Up to 6 months
Environmental impact of study-related procedures
기간: Up to 6 months

The environmental footprint of each component of the research process will be assess, including:

  • Biological sampling: Biomarkers will be measured from routine care tubes, avoiding the use of dedicated research tubes, which often expire unused and contribute to waste.
  • Patient transport: No additional on-site visits will be required for the study, limiting travel-related emissions (Lyle et al., BMJ, 2009).
  • Study documentation: Digital consent forms (e-consent) will be preferred. When choosing between paper or electronic formats, the environmental impact of printing, document replacement after amendments, and digital storage will be considered.

All study procedures will be reviewed according to the guidance proposed by Griffiths et al. (BMJ Open, 2024), which identified high-impact areas in clinical trials. The goal is to apply these recommendations throughout the study.

Up to 6 months
Life cycle analyse (LCA)
기간: Up to 6 months

Life cycle analyses (LCA) of the new algorithm and its associated device. It will be based on the Life Cycle Assessment (LCA) framework proposed by Ashby (Materials and the Environment, 2013), using Granta EduPack® software tools.

Up to 6 months
LCA comparison of the two clinical strategies
기간: Up to 6 months

The two clinical strategies will be compared using LCA to assess their respective environmental impacts from patient inclusion to the end of follow-up. This approach is inspired by previous work (Makhloufi et al., Nephrol Dial Transplant, 2024), integrating medical and ecological outcomes.

The average carbon emissions and water consumption between the two groups will be compared by collecting all activities from the time of inclusion until the end of follow-up in the study.

Up to 6 months

기타 결과 측정

결과 측정
측정값 설명
기간
Circulating levels of C-reactive protein, procalcitonin, NETs, neutrophil degranulation markers, cytokines and chemokines
기간: At baseline, day 1 and day 7
At baseline, day 1 and day 7
Multi-omic profile
기간: At baseline

Characterization of blood transcriptomic (RNA expression), proteomic (protein abundance) and metabolomic (metabolite abundance) profiles, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis. No DNA analyses will be performed.

At baseline
Multi-omic profile
기간: At day 1

Characterization of blood transcriptomic (RNA expression), proteomic (protein abundance) and metabolomic (metabolite abundance) profiles, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis. No DNA analyses will be performed.

At day 1
Multi-omic profile
기간: At day 7

Characterization of blood transcriptomic (RNA expression), proteomic (protein abundance) and metabolomic (metabolite abundance) profiles, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis. No DNA analyses will be performed.

At day 7
Innate immune cells activation markers and sub-populations
기간: At baseline

Characterization of peripheral blood innate immune cell subpopulation frequencies and activation-marker expression, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis.

At baseline
Innate immune cells activation markers and sub-populations
기간: At day 1

Characterization of peripheral blood innate immune cell subpopulation frequencies and activation-marker expression, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis.

At day 1
Innate immune cells activation markers and sub-populations
기간: At day 7

Characterization of peripheral blood innate immune cell subpopulation frequencies and activation-marker expression, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis.

At day 7

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 의자: Djillali Annane, MD PhD, IHU SEPSIS - PROMETHEUS Comprehensive Sepsis Center, AP-HP, Université Paris-Saclay

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 12월 1일

기본 완료 (추정된)

2027년 12월 2일

연구 완료 (추정된)

2028년 6월 1일

연구 등록 날짜

최초 제출

2026년 10월 30일

QC 기준을 충족하는 최초 제출

2026년 11월 11일

처음 게시됨 (실제)

2026년 11월 17일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 17일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 11일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • APHP260617

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

According to DETECSEPS consortium data management plan, upon request to IHU SEPSIS and to APHP

IPD 공유 기간

Within 6 months from publication of the study results

IPD 공유 액세스 기준

Upon request to IHU SEPSIS and to APHP according to the data management plan of the Consortium

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .